|
Synonyms: h-R3 | THERACIM® | Theraloc®
nimotuzumab is an approved drug (China, India, others (2014))
Compound class:
Antibody
Comment: Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 [1]. Biosimilar drug: Biocon Limited are developing BIOMAb-EGFRTM as a nimotuzumab biosimilar |
| Bioactivity Comments |
| Patent US6506883 [1] does not include an affinity value for the interaction between nimotuzumab and the EGFR. |
